IMVT Stock Summary and Trading Ideas (Immunovant | NASDAQ:IMVT)

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Immunovant trades on the NASDAQ stock market under the symbol IMVT.

As of January 30, 2026, IMVT stock price declined to $26.00 with 1,761,842 million shares trading.

IMVT has a beta of 1.26, meaning it tends to be more sensitive to market movements. IMVT has a correlation of 0.15 to the broad based SPY ETF.

IMVT has a market cap of $5.24 billion. This is considered a Mid Cap stock.

In the last 3 years, IMVT traded as high as $45.58 and as low as $12.72.

The top ETF exchange traded funds that IMVT belongs to (by Net Assets): VTI, XBI, VB, IWM, VXF.

IMVT has outperformed the market in the last year with a return of +17.8%, while the SPY ETF gained +15.6%. In the last 3 month period, IMVT beat the market returning +4.8%, while SPY returned +2.1%. However, in the most recent 2 weeks IMVT has underperformed the stock market by returning -1.0%, while SPY returned 0.0%.

IMVT support price is $25.64 and resistance is $27.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMVT shares will trade within this expected range on the day.